|Cat. No. :
|Product Overview :
||Recombinant human VEGFR3 was expressed by baculovirus inSf9 insect cellsusing a N-terminal GST tag. MW=82kDa.
||The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis.
||Sf9 insect cells using baculovirus.
|Specific Activity :
|Assay Condition :
||VEGFR3 was incubated with a substrate (Tyr peptide 4) for 1h at RT in 1Xkinase buffer supplemented with ATP. Developer solution was added to reaction and reaction was stopped after 1h of incubation at RT.
||Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
|Formulated In :
||25 mM Tris-HCl, pH 8.0, 138 mM NaCl, 0.05% Tween-20, 20% glycerol and 3mM DTT.
||>6 months at –80°C.